Mali
Tuberculosis profile
| High HIV burden |
Population  2012 15 million
Estimates of TB burden * 2012 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.3 (0.63–2.3) 9 (4.3–15)
Mortality (HIV+TB only) 0.36 (0.31–0.42) 2.4 (2.1–2.8)
Prevalence  (includes HIV+TB) 14 (7.6–22) 92 (51–146)
Incidence  (includes HIV+TB) 9 (8.5–9.4) 60 (57–63)
Incidence (HIV+TB only) 1.2 (1.2–1.3) 8.2 (7.8–8.6)
Case detection, all forms (%) 61 (58–64)    
TB case notifications 2012        
New cases   (%) Retreatment cases (%)
Smear-positive 3 724 (70) Relapse 154 (50)
Smear-negative 487 (9) Treatment after failure 98 (32)
Smear-unknown / not done 0 (0) Treatment after default 58 (19)
Extrapulmonary 1 081 (20) Other 0 (0)
Other 0 (0)      
Total new 5 292   Total retreatment 310  
           
Other (history unknown) 0        
Total new and relapse 5 446   Total cases notified 5 602  
New cases Smear-positive Smear-negative/ unknown/
not done
Extrapulmonary
M:F ratio 2.2    
Age < 15 59 44 98
Laboratories 2012
Smear (per 100 000 population) 0.4
Culture (per 5 million population) 1.0
Drug susceptibility testing (per 5 million population) 0.3
Is second-line drug susceptibility testing available? No
Treatment success rate 2011 (%)        
New smear-positive and/or culture-positive 68   Is rifampicin used
throughout treatment for
new patients?
Yes
New smear-negative/extrapulmonary 72  
Retreatment 69  
TB/HIV 2012 Number (%)
TB patients with known HIV status 1 544 (28)
HIV-positive TB patients 425 (28)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 179 (42)
HIV-positive TB patients on antiretroviral therapy (ART) 425 (100)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Estimates of MDR-TB burden 2012*   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.1–3.4) 19 (7.4–31)
MDR-TB cases among notified pulmonary
TB cases
76 (4–140) 60 (23–96)
Reported cases of MDR-TB 2012 New Retreatment Total
Cases tested for MDR-TB 23 (<1%) 39 (13%) 62
Laboratory-confirmed MDR-TB cases 0 12 12
Patients started on MDR-TB treatment     40
Financing TB control 2013
National TB programme budget (US$ millions) 2.4
% Funded domestically 44%
% Funded internationally 56%
% Unfunded 0%
***
(Rate per 100 000 population per year)
Mortality graph
___ Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
___ Prevalence

(Rate per 100 000 population per year)
Incidence graph
__ Notifications Incidence
___
___ Incidence (HIV+TB only)

Treatment success rate (%)
tx success graph
__ New smear-positive and/or culture-positive
__ New smear-negative/extrapulmonary __
Retreatment

(Number of patients)
CPT ART graph
__ HIV-positive TB patients
__ on CPT __ on ART

Total budget (US$ millions)
Budget funding Graph
__ Funded domestically __ Funded internationally
__ Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 * Ranges represent uncertainty intervals Generated: 2014-04-24 Data: www.who.int/tb/data